Molly Campbell is a Senior Science Writer and Editor. She specializes in topics such as AI, psychedelics, coronavirus, CRISPR, and FDA regulations, exploring the intersection of technology and health. Molly's work has been featured in Technology Networks and the Center for a New American Security (CNAS).
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
Not enough data
Molly Campbell's coverage primarily focuses on scientific topics, particularly genetics, neuroscience, biology, medical research and health. She heavily relies on data for her articles.
To effectively reach out to Molly, consider providing pitches with access to new and significant scientific data or studies related to genetics, neuroscience, biology or health. This could include exclusive access to researchers or experts conducting groundbreaking work in these fields.
As she doesn't have a specific geographic focus indicated but covers global scientific developments extensively without any regional bias apparent in the article titles provided.
This information evolves through artificial intelligence and human feedback. Improve this profile .
By: Molly Campbell
Bruker Corporation officially opened its new production facility in Bremen – one of Germany’s major science hubs – last week. Technology Networks visited the facility to learn about its low carbon footprint and how it will support Bruker's commitment to innovation and collaboration.
Cell separation refers to processes that are used to separate a single cell – or a population of cells – from a heterogenous cell mixture.
By: Molly Campbell, Alexander Beadle
Dr. Omid Farokhzad, chair and CEO at Seer, discusses how to achieve deep, unbiased and scalable analysis of the proteome at speed at ASMS 2024.
By: Molly Campbell, Alexander Beadle
Technology Networks joined SCIEX for a discussion about the company’s latest product launches at this year’s ASMS conference.
In this article, we take a look at the latest advancements in research applying multiplex CRISPR-Cas9 genome editing to plants.
By: Alexander Beadle, Molly Campbell
John Lesica, president of chromatography and mass spectrometry at Thermo Fisher Scientific, joined Technology Networks for an interview at this year's American Society for Mass Spectrometry event.
By: Molly Campbell, Sarah Whelan
To learn more about the FDA's pending decision on MDMA-assisted therapy for PTSD, Technology Networks interviewed Dr. Sam Clark, CEO of Terran Biosciences, who leads one of the industry’s largest psychedelic development programs.
The breakdown of biological material by microbes is an integral process to life on Earth. While some genetic studies have probed the microbial communities that
Fungi aficionados have reason to rejoice, as two new species of Psilocybe mushrooms – best known for their psychoactive properties – have been discovered in South Africa.
By: Anna Pederson, Molly Campbell
Analysis from CNAS experts on the most critical challenges for U.S. foreign policy.
(833) 317-6278 
